A staff member tests samples of the COVID-19 inactivated vaccine at a vaccine production base of Beijing Institute of Biological Products Co, Ltd. in Beijing, on April 11, 2020. The inactivated vaccine is developed by Sinopharm. (Xinhua/Zhang Yuwei) BEIJING, May 27 (Xinhua) Two inactivated vaccines developed by the Chinese pharmaceutical giant Sinopharm have shown to be safe and effective against COVID-19 in phase-3 human trials, according to.
2021-05-27 05:05:16 GMT2021-05-27 13:05:16(Beijing Time) Xinhua English
BEIJING, May 27 (Xinhua) Two inactivated vaccines developed by the Chinese pharmaceutical giant Sinopharm have shown to be safe and effective against COVID-19 in phase-3 human trials, according to a study published this week in The Journal of the American Medical Association.
The randomized, double-blind and placebo-controlled trials were designed by the Wuhan Institute of Biological Products Co, Ltd, and the Beijing Institute of Biological Products Co, Ltd, both of which belong to the China National Biotec Group(CNBG), affiliated with Sinopharm.
It is the world s first published phase-3 study results of inactivated COVID-19 vaccines, the CNBG said in a statement on Thursday.
Geneva [Switzerland], May 27 (ANI): The World Health Organization (WHO) is seeking more data on China's Sinovac Biotech-made COVID-19 vaccine, named CoronaVac, as it weighs whether to authorise a second Chinese vaccine under international pressure to help distribute more shots.